Updates in the Treatment of Mantle Cell Lymphoma This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.
Newsletter Stay up to date on the most recent and practice-changing oncology data
Subscribe
November 9th, 2026 Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
November 22nd, 2026 The top 5 OncLive TV videos of the week cover insights in NSCLC, HER2+ gastroesophageal cancer, low-grade glioma, HR+ breast cancer, and CML.
November 21st, 2026 The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.
November 20th, 2026 Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
November 18th, 2026 Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.
November 11th, 2026 A meta-analysis of 4 sonrotoclax cohorts showed consistent response activity and low tumor lysis rates in heavily pretreated mantle cell lymphoma.
November 10th, 2026 The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.